<i>In silico</i> prediction of T‐cell and B‐cell epitopes of human papillomavirus type 16 L1 protein

Mahmoudvand, Shahab; Shokri, Somayeh; Makvandi, Manoochehr; Taherkhani, Reza; Rashno, Mohammad; Jalilian, Farid Azizi; Angali, Kambiz Ahmadi

doi:10.1002/bab.2128

Cited by 9 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the studies conducted by Negahdaripour et al, the HPV16 L2 protein was used to predict the epitope 41 , 42 , while Sarkar et al 43 . and Mahmoudvand et al 44 used L1 protein to predict the epitope. In another study, Namvar et al selected the E5 and E7 proteins from HPV16/18/31/45 as target proteins for epitope prediction 45 .…”

Section: Discussionmentioning

confidence: 99%

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches

Sanami

Azadegan‐Dehkordi

Rafieian-Kopaei

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Cervical cancer, caused by human papillomavirus (HPV), is the fourth most common type of cancer among women worldwide. While HPV prophylactic vaccines are available, they have no therapeutic effects and do not clear up existing infections. This study aims to design a therapeutic vaccine against cervical cancer using reverse vaccinology. In this study, the E6 and E7 oncoproteins from HPV16 were chosen as the target antigens for epitope prediction. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) epitopes were predicted, and the best epitopes were selected based on antigenicity, allergenicity, and toxicity. The final vaccine construct was composed of the selected epitopes, along with the appropriate adjuvant and linkers. The multi-epitope vaccine was evaluated in terms of physicochemical properties, antigenicity, and allergenicity. The tertiary structure of the vaccine construct was predicted. Furthermore, several analyses were also carried out, including molecular docking, molecular dynamics (MD) simulation, and in silico cloning of the vaccine construct. The results showed that the final proposed vaccine could be considered an effective therapeutic vaccine for HPV; however, in vitro and in vivo experiments are required to validate the efficacy of this vaccine candidate.

show abstract

Section: Discussionmentioning

confidence: 99%

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches

Sanami

Azadegan‐Dehkordi

Rafieian-Kopaei

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Immunoinformatics approach has been widely utilized to identify the most effective epitopes for the development of multi-epitope vaccines against a variety of pathogens. 33 The immunoinformatics approach is particularly beneficial for vaccine design due to its affordability. Several researches have used immunoinformatics method to develop vaccines against organisms, such as bacteria, viruses, and parasites in recent years.…”

Section: Discussionmentioning

confidence: 99%

Design of a multi‐epitope‐based vaccine consisted of immunodominant epitopes of structural proteins of SARS‐CoV‐2 using immunoinformatics approach

Mahmoudvand

Ghaleh

Jalilian

et al. 2023

Biotech and App Biochem

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has shown rapid global spread and has resulted in a significant death toll worldwide. In this study, we aimed to design a multi‐epitope vaccine against SARS‐CoV‐2 based on structural proteins S, M, N, and E. We identified B‐ and T‐cell epitopes and then the antigenicity, toxicity, allergenicity, and similarity of predicted epitopes were analyzed. T‐cell epitopes were docked with corresponding HLA alleles. Consequently, the selected T‐ and B‐cell epitopes were included in the final construct. All selected epitopes were connected with different linkers and flagellin and pan‐HLA DR binding epitopes (PADRE) as an adjuvant were used in the vaccine construct. Furthermore, molecular docking was used to evaluate the complex between the final vaccine construct and two alleles, HLA‐A*02:01 and HLA‐DRB1*01:01. Finally, codons were optimized for in silico cloning into pET28a(+) vector using SnapGene. The final vaccine construct comprised 11 CTL, HTL, and B‐cell epitopes corresponding to 394 amino acid residues. In silico evaluation showed that the designed vaccine might potentially promote an immune response. Further in vivo preclinical and clinical testing is required to determine the safety and efficacy of the designed vaccine.

show abstract

“…22 E6, E7, and L1 proteins appear to be promising vaccine candidates due to the presence of numerous known neutralising epitopes. 23 It is crucial to understand the vaccine candidate's structural characteristics, such as its secondary structure. Alpha helix and coilcontaining proteins and peptides are significant structural antigens because antibodies can identify them.…”

Section: Discussionmentioning

confidence: 99%

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens

Padavu¹,

Kumar²,

Kumar³

et al. 2023

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Globally, cervical cancer is the fourth most common cancer among women. After being cloned from a recurring cervical lesion in 1987, Human papillomavirus (HPV) type-45 was identified as a high-risk HPV type. It is the third most common cancer-causing HPV subtype, after HPV-16 and HPV-18. Immunogenic epitopes and structural features provide the most useful information for vaccine development. Computational algorithms provide quick, simple, trustworthy, and cost-efficient methods for predicting immunogenic epitopes. In this study, both B and T cell epitopes have been identified as potential immunogens that can elicit a response from the host system. Three potential B-cell epitopes, i.e., SIAGQYRGQCNTCCDQ, LQEIVLHLEPQNELDP, and DSTVYLPPPSVARVVS, were identified in this study. A potential epitope for E6 (ATLERTEVY) was predicted to 8 MHC-I alleles (HLA-A*30:02, HLA-B*15:01, HLA-A*01:01, HLA-A*26:01, HLA-A*32:01, HLA-B*35:01, HLA-B*58:01, HLA-A*11:01) and for L1 epitope (NVFPIFLQM) was predicted for 4 MHC-I alleles (HLA-A*30:02, HLA-A*32:01, HLA-B*53:01, HLA-B*51:01). To conclude, the epitopes identified here might potentially be useful for developing a cervical cancer vaccine against HPV-45 strains, but in vitro and in vivo trials are needed to validate their safety and efficacy.

show abstract

In silico prediction of T‐cell and B‐cell epitopes of human papillomavirus type 16 L1 protein

Cited by 9 publications

References 44 publications

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches

Design of a multi‐epitope‐based vaccine consisted of immunodominant epitopes of structural proteins of SARS‐CoV‐2 using immunoinformatics approach

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens

Contact Info

Product

Resources

About